Study summary · research use only
Tirzepatide
Abstract
Tirzepatide is an agonist of the receptors of two insulin sensitizing polypeptides, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide 1), that is used as therapy of type 2 diabetes, obstructive sleep apnea, and obesity. Tirzepatide has been linked to minimal instances of elevations in serum aminotransferase levels during therapy and rare episodes of clinically apparent liver injury.
pepmg summarizes the peer-reviewed literature and links to every source. It sells nothing and ships nothing. Where an FDA label, a peer-reviewed study or a clinical-trial registry entry (labeled trial registry, not peer-reviewed) has published a dose, pepmg reports it with the source named; it gives no personalized recommendations and no administration technique. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.